Open AccessExperimental study of the possibility of reducing the cardiotoxic effects of “Mitomycin C” using an immobilized form of “Mitomycin C” and cytoprotector
Author(s) -
Gladchenko Mikhail P.,
E. B. Artyushkova,
Frolova Oxana G.,
Г. С. Маль,
В. В. Хвостовой,
Bykanova Anna M.,
Marina A. Chernyatina,
Puchak Irina R.
Publication year - 2022
Publication title -
čelovek i ego zdorovʹe
Language(s) - English
Resource type - Journals
eISSN - 1998-5754
pISSN - 1998-5746
DOI - 10.21626/vestnik/2021-3/06
Subject(s) - mitomycin c , pharmacology , medicine , intraperitoneal injection , cardiotoxicity , drug , chemotherapy , surgery
The objective of this work was to investigate in experiments on laboratory rats the possibility of reducing the cardiotoxicity of the anticancer drug Mitomycin C by mixing it with Mesogel before injection and using Mexicor® as a cardioprotective agent. Materials and methods. To carry out the study, 70 male Wistar rats were used. The body weight of laboratory animals at the beginning of the experimental study ranged from 180 to 220 grams. Intraperitoneal administration of Mitomycin C at a dose of 4 mg/kg once at the start of the study was used. When Mitomycin C was administered together with Mesogel, the drugs were combined under aseptic conditions before intraperitoneal administration, and Mesogel was administered at a volume of 10.7 ml/kg. The drug Mexicor® was administered in the form of intramuscular injections at a dose of 60 mg/kg per day for 14 days. Results. After intraperitoneal injection of the drug "Mitomycin C" at a dose of 4 mg / kg, a noticeable decrease in the contractility of the rat myocardium during exercise tests was observed only on the 14th day. The use of "Mitomycin C" mixed with "Mesogel" during intraperitoneal administration had a positive effect, but did not completely exclude the manifestation of the cardiotoxic effects of "Mitomycin C". The greatest efficiency was demonstrated in groups of animals that received "Mitomycin C" in a mixture with "Mesogel" together with the cytoprotective drug "Mexicor®". Conclusion. The combination of "Mitomycin C" immobilisation in "Mesogel" together with the cytoprotective drug "Mexicor®" was found to eliminate the cardiotoxic effects of "Mitomycin C" to the greatest extent.